<DOC>
	<DOC>NCT02391259</DOC>
	<brief_summary>This is a multicenter, randomized, double-blind, placebo-controlled, sequential rising single-dose study in which approximately 56 subjects with SLE will be enrolled in 7 dosing cohorts</brief_summary>
	<brief_title>A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Diagnosis of SLE with positive ANA Stable disease with no change in SLE therapy within the previous 30 days BMI from 18 to 38 kg/m2 Have had signs or symptoms of a viral, bacterial or fungal infection within 30 days of study randomization Evidence of renal disease or liver disease Any history of granulomatous disease including autoimmune granulomatous vasculitis and sarcoidosis Prior administration of any other biologic that primarily targets the immune system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>